<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000626</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 149</org_study_id>
    <secondary_id>11124</secondary_id>
    <nct_id>NCT00000626</nct_id>
  </id_info>
  <brief_title>Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease</brief_title>
  <official_title>Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Primary: To assess the toxicity of chemotherapy with ABVD (doxorubicin / bleomycin /&#xD;
      vinblastine / dacarbazine) when given with filgrastim ( granulocyte colony-stimulating&#xD;
      factor; G-CSF ) in patients with underlying HIV infection and Hodgkin's disease; to observe&#xD;
      the efficacy of ABVD and G-CSF in reducing tumor burden in HIV-infected patients with&#xD;
      Hodgkin's disease.&#xD;
&#xD;
      Secondary: To determine the durability of tumor response to ABVD plus G-CSF over the 2-year&#xD;
      study period; to observe the incidence of bacterial and opportunistic infections in&#xD;
      HIV-infected patients with Hodgkin's disease receiving this regimen; to document quality of&#xD;
      life of patients receiving this regimen.&#xD;
&#xD;
      Addition of granulocyte colony-stimulating factor may prevent neutropenia caused by&#xD;
      chemotherapy, allowing more timely administration of chemotherapy and improved response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Addition of granulocyte colony-stimulating factor may prevent neutropenia caused by&#xD;
      chemotherapy, allowing more timely administration of chemotherapy and improved response.&#xD;
&#xD;
      Study drugs are administered in 28-day cycles to twenty-seven HIV-infected patients with&#xD;
      Hodgkin's disease. ABVD (doxorubicin / bleomycin / vinblastine / dacarbazine) is administered&#xD;
      on days 1 and 15 of each cycle, and G-CSF is given on days 2 through 14 and 16 through 28 of&#xD;
      each cycle. All patients receive four cycles of treatment and are then restaged. Patients&#xD;
      with a complete response (CR) following the initial four cycles receive two additional cycles&#xD;
      of ABVD / G-CSF. Patients with a partial response following the initial four cycles receive&#xD;
      two additional cycles of ABVD / G-CSF and are again restaged; those who have achieved a CR at&#xD;
      that point then receive two more cycles, while those without CR discontinue study therapy.&#xD;
      Patients with disease progression following the initial four cycles of therapy discontinue&#xD;
      treatment on the study. Concomitant PCP prophylaxis is administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 1999</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>27</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hodgkin's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  PCP prophylaxis consisting of Bactrim, aerosolized pentamidine, or dapsone.&#xD;
&#xD;
        Recommended:&#xD;
&#xD;
          -  Antiemetic therapy within 30 minutes of chemotherapy.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral medication after two cycles of chemotherapy, provided the patient has&#xD;
             not experienced grade 3 neutropenia while on chemotherapy or on previous&#xD;
             antiretroviral therapy.&#xD;
&#xD;
          -  Acetaminophen and/or nonsteroidal anti-inflammatory agents.&#xD;
&#xD;
          -  Bone marrow-suppressive agents, such as ganciclovir, Fansidar, Bactrim, and dapsone.&#xD;
&#xD;
          -  Maintenance therapy for chronic opportunistic infection.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Cranial irradiation (2400 rads) for patients with CNS involvement.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection or diagnosis of AIDS.&#xD;
&#xD;
          -  Hodgkin's disease.&#xD;
&#xD;
          -  Consent of parent or guardian and have care directly supervised by a pediatric&#xD;
             oncologist if under 18 years of age.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Maintenance therapy for opportunistic infections.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Second primary cancer other than Kaposi's sarcoma that does not require systemic&#xD;
             therapy, nonmelanomatous skin cancer, Bowen's disease, or carcinoma in situ of the&#xD;
             cervix.&#xD;
&#xD;
          -  Acute, active bacterial or opportunistic infection requiring ongoing therapy if such&#xD;
             therapy has been initiated within the past 2 weeks.&#xD;
&#xD;
          -  Known hypersensitivity (e.g., anaphylactoid reaction, bronchospasm) to E. coli-derived&#xD;
             proteins.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior chemotherapy for Hodgkin's disease.&#xD;
&#xD;
          -  Antiretroviral therapy within 2 weeks prior to study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior radiotherapy for Hodgkin's disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Levine A</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900331079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis ConnectCare, Infectious Diseases Clinic</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>432101228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50. doi: 10.1097/00126334-200008150-00009.</citation>
    <PMID>11035615</PMID>
  </reference>
  <reference>
    <citation>Levine AM, et al. Prospective, multicenter phase II trial of ABVD chemotherapy with G-CSF in HIV-infected patients with Hodgkin's disease (HD): AIDS Clincial Trials Group (ACTG) Study 149. Proc Annu Meet Am Soc Clin Oncol. 1997;16:A194</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulocyte Colony-Stimulating Factor</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antineoplastic Agents, Combined</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>ABVD protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

